Neuren Pharmaceuticals company profile

NEU · ASX · AUD

Compare Neuren Pharmaceuticals
$20.97Change from previous close: −4.73%Absolute change: −$1.04

Close · November 20, 2026

Company profile

Neuren Pharmaceuticals has 8 employees and is headquartered in Hawthorn East, Australia.

With eight employees and revenue of AUD 64.6 million in the fiscal year ended December 2025, Neuren Pharmaceuticals develops drugs for neurological disorders. It develops and commercializes DAYBUE (trofinetide) for Rett syndrome in adults and in patients aged 2 years and older, and runs a Phase 2 trial for Fragile X syndrome. Its NNZ-2591 compound has completed Phase 2 testing for Phelan-McDermid syndrome, is in Phase 2 for Angelman and Pitt Hopkins syndromes, and is in preclinical stage for Prader-Willi syndrome, hypoxic ischemic encephalopathy and SYNGAP1.

Net profit for the same fiscal year was AUD 30.4 million, while revenue fell 70.2% compared with the prior fiscal year. The company was incorporated in 2001 and has its headquarters in Hawthorn East, Australia, where it employs eight people.

Company facts

Industry
Biotechnology
Country
Australia
Headquarters
117 Camberwell Road, 3123, Hawthorn East
Employees
8
Chief executive
Jonathan Pilcher
Founded
2001
Fiscal year
January - December
Listing
NEU · ASX
Currency
AUD
ISIN
NZNEUE0001S8

Neuren Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Neuren PharmaceuticalsNEUAustralia$1.83B819.9%144.0
MesoblastMSBAustralia$1.48B108-42.6%—
InSilico Medicine Cayman TopCo3696Hong Kong SAR China$2.59B333-6.9%—
Telix PharmaceuticalsTLXAustralia$2.92B1,1206.2%92.3
Metis TechBio7666Hong Kong SAR China$1.11B150-131.2%—
3SBio1530Hong Kong SAR China$4.56B6,06860.3%3.90

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Neuren Pharmaceuticals with its competitors